Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic.
Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic.
复制标题
结核疫苗卡介苗：老疫苗在抗击COVID-19大流行中的神奇功效。
DOI：
10.1080/08830185.2021.1922685
复制
发表时间：
2022
影响因子：
5
通讯作者：
Parkkila S
中科院分区：
文献类型：
--
作者：
Aspatwar A;Gong W;Wang S;Wu X;Parkkila S
卡介苗(BCG)是一种牛分枝杆菌减毒活疫苗，由阿尔伯特·卡梅特和卡米尔·盖林于100年前研制成功。许多国家几十年来一直在使用这种疫苗来预防结核病。世界卫生组织(WHO)建议在结核病流行和麻风病高危国家的婴儿接种单剂卡介苗，全球每年有近1.3亿婴儿接种疫苗。卡介苗在降低新生儿和儿童死亡率方面的作用是众所周知的。流行病学和回顾性横断面研究表明，卡介苗接种可保护儿童免受呼吸道感染，并降低儿童患疟疾的风险。此外，卡介苗还可提高干扰素-γ和IL-10水平，从而为老年人提供对呼吸道感染的免疫力。卡介苗还能通过一种被称为“训练免疫”的先天免疫机制，提供针对病毒和寄生虫的非特异性先天免疫，并被定义为通过表观遗传重新编程对先天免疫系统的免疫召回。基于这些研究，我们认为卡介苗有潜力作为新冠肺炎的保护剂。进一步证实的卡介苗在人体内的安全记录、其佐剂活性和低成本制造使其成为阻止这一大流行并降低与新冠肺炎相关的死亡率的有吸引力的选择。在这篇综述中，我们讨论了卡介苗的异源效应，训练性免疫的诱导，以及它在潜在的新冠肺炎疫苗开发中的意义。
Bacillus Calmette-Guérin (BCG) is a live attenuated M. bovis vaccine that was developed about 100 years ago by Albert Calmette and Camille Guérin. Many countries have been using the vaccine for decades against tuberculosis (TB). The World Health Organization (WHO) recommends a single dose of BCG for infants in TB endemic as well as leprosy high risk countries, and globally almost 130 million infants are vaccinated yearly. The role of BCG is well known in reducing neonatal and childhood death rates. Epidemiological and retrospective cross-sectional studies demonstrated that the BCG vaccination protects the children against respiratory tract infections and lowers the risk of malaria in children. In addition, BCG enhances IFN-γ and IL-10 levels, thus providing immunity against respiratory tract infection even in elderly people. The BCG is also known to provide nonspecific innate immunity against viruses and parasites, through an innate immune mechanism termed ‘trained immunity’ and is defined as the immunological recall of the innate immune system by epigenetic reprogramming. Based on these studies it is suggested that the BCG has the potential to act as a protective agent against COVID-19. Further proven safety records of BCG in humans, its adjuvant activity and low-cost manufacturing make it an attractive option to stop the pandemic and reduce the COVID-19 related mortality. In this review we discuss the heterologous effects of BCG, induction of trained immunity and its implication in development of a potential vaccine against COVID-19 pandemic.
登录
查看更多内容
影响因子：
11.8
作者：
de Chaisemartin, Clement;de Chaisemartin, Luc
通讯作者：
de Chaisemartin, Luc
影响因子：
28.3
作者：
Gorbalenya, Alexander E.;Baker, Susan C.;Ziebuhr, John
通讯作者：
Ziebuhr, John
影响因子：
4.6
作者：
Aksu, K.;Naziroglu, T.;Ozkan, P.
通讯作者：
Ozkan, P.
影响因子：
11.8
作者：
BREWER, TF;COLDITZ, GA
通讯作者：
COLDITZ, GA
影响因子：
168.9
作者：
Fine, PEM;Ponnighaus, JM;Peto, R
通讯作者：
Peto, R